A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone

References

• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017;10:965–981.
   PubMed Web of Science ®Google Scholar
• Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–1369.
   PubMed Web of Science ®Google Scholar
• Dopheide JA. Paliperidone: an improvement over risperidone? Am J Health Syst Pharm. 2008;65:401.
   PubMed Web of Science ®Google Scholar
• Cleton A, Rossenu S, Vermeulen A, et al. A pharmacokinetic model to document the interconversion between paliperidone enantiomers. Clin Pharmacol Ther. 2006;79:55.
   Web of Science ®Google Scholar
• Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005;315:1278–1287.
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29–39.
   PubMed Web of Science ®Google Scholar
• Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57–73.
   PubMed Web of Science ®Google Scholar
• Leysen JE, Janssen PM, Megens AA, et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55(Suppl):5–12.
   PubMed Web of Science ®Google Scholar
• Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927–942.
   PubMed Web of Science ®Google Scholar
• Citrome L. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol. 2012;8:873–888.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Choi JS, Choi BH, et al. Inhibition of cloned hERG potassium channels by risperidone and paliperidone. Naunyn-Schmiedebergs Arch Pharmacol. 2017;390:633–642.
   PubMed Web of Science ®Google Scholar
• Titier K, Déridet E, Moore N. In vivo and in vitro myocardial binding of risperidone and 9-hydroxyrisperidone. Toxicol Appl Pharmacol. 2002;15(180):145–149.
   Google Scholar
• Vigneault P, Kaddar N, Bourgault S, et al. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? J Cardiovasc Pharmacol. 2011;57:690–695.
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Kambayashi R, Aimoto M, et al. A. In vivo analysis of torsadogenic potential of an antipsychotic drug paliperidone using the acute atrioventricular block rabbit as a proarrhythmia model. J Pharmacol Sci. 2016;132:48–54.
   PubMed Web of Science ®Google Scholar
• Chiba K, Wada T, Nakamura Y, et al. Analysis of proarrhythmic potential of an atypical antipsychotic drug paliperidone in the halothane-anesthetized dogs. J Pharmacol Sci. 2017;134:239–246.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Fukui N, Watanabe J, et al. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Hum Psychopharmacol. 2012;27:39–42.
   PubMed Web of Science ®Google Scholar
• Ito A, Enokiya T, Kawamoto E, et al. Two cases of life-threatening arrhythmia induced by risperidone: evaluation of risperidone and 9-hydroxy-risperidone concentrations. Acute Med Surg. 2017;4:341–343.
   PubMed Web of Science ®Google Scholar
• Vieweg WV, Hasnain M, Hancox JC, et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. Psychopharmacology (Berl). 2013;228:515–524.
   PubMed Web of Science ®Google Scholar
• Tsay ME, Klein-Schwarz W, Anderson B. Toxicity and clinical outcomes of paliperidone exposures reported to U.S. poison centers. Clin Toxicol (Phila). 2014;52:207–213.
   PubMed Web of Science ®Google Scholar
• Chang JP, Huang CC, Su KP. Paliperidone overdose in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;17(34):418.
   Google Scholar
• Gill JS, Pillai SK, Koh OH, et al. Non-fatal paliperidone overdose: a case report. Turk Psikiyatri Derg. 2010;21:331–334.
   PubMed Web of Science ®Google Scholar
• Levine M, Lovecchio F, Tafoya P, et al. Paliperidone overdose with delayed onset of toxicity. Ann Emerg Med. 2011;58:80–82.
   PubMed Web of Science ®Google Scholar
• Wong LY, Greene SL, Odell M, et al. Severe prolonged posture-evoked tachycardia after massive overdose of paliperidone. Clin Toxicol (Phila). 2016;54:535.
   PubMed Web of Science ®Google Scholar
• Villa A, Gallotta G, Malaguti A, et al. Dyskinesia, cardiac arrhythmia and partial seizure associated with paliperidone overdose: a case report. Ital J Med. 2015;9:373–376.
   Web of Science ®Google Scholar
• Crauwels H, Rossenu S, Cleton A, et al. Bioequivalence study of two paliperidone extended-release formulations. AAPS J. 2006;8(S2):1371.
   Google Scholar
• Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone ER in healthy subjects. Schizophr Res. 2006;81:85–86.
   Web of Science ®Google Scholar
• Rossenu S, Crauwels H, Cleton A, et al. Evaluation of the pharmacokinetics of several formulations of paliperidone. AAPS J. 2006;8(S2):1371.
   Google Scholar
• Rossenu S, Crauwels H, Cleton A, et al. Extended-release formulation of paliperidone shows dose proportional pharmacokinetics. AAPS J. 2006;8(S2):3123.
   Google Scholar
• Cleton A, Rossenu S, Boom S, et al. Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects. Clin Pharmacol Ther. 2007;81(Suppl):64.
   Google Scholar
• Cleton A, Thijssen A, Van Osseelaer N, et al. Effects of renal impairment on the pharmacokinetic profile of paliperidone extended-release tablets. Clin Pharmacol Ther. 2007;81(Suppl):63.
   Google Scholar
• Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36:769–779.
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Cleton A, Herben V, et al. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry. 2009;42:158–163.
   PubMed Web of Science ®Google Scholar
• Boom S, Talluri K, Janssens L, et al. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol. 2009;49:1318–1330.
   PubMed Web of Science ®Google Scholar
• Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther. 2009;47:606–616.
   PubMed Web of Science ®Google Scholar
• Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol. 2009;24:532–539.
   PubMed Web of Science ®Google Scholar
• Remmerie B, Ariyawansa J, De Meulder M, et al. Drug-drug interaction studies of paliperidone and divalproex sodium extended-release tablets in healthy participants and patients with psychiatric disorders. J Clin Pharmacology. 2016;56:683–692.
   PubMed Web of Science ®Google Scholar
• Kerbusch-Herben V, Cleton A, Berwaerts J, et al. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state. Clin Pharmacol Drug Dev. 2014;3:371–377.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals. INVEGA® (paliperidone) extended-release tablets; Drug label information. Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2007.
   Google Scholar
• Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab. 2010;11:516–525.
   PubMed Web of Science ®Google Scholar
• de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80–88.
   PubMed Web of Science ®Google Scholar
• Lisbeth P, Vincent H, Kristof M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016;72:175–184.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Kubo K, Ishioka M, et al. Interaction between paliperidone and carbamazepine. Ther Drug Monit. 2013;35:649–652.
   PubMed Web of Science ®Google Scholar
• Akamine Y, Uehara H, Miura M, et al. Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine. J Clin Pharm Ther. 2015;40:480–482.
   PubMed Web of Science ®Google Scholar
• Müller F, König J, Hoier E, et al. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol. 2013;15:808–815.
   Google Scholar
• Cassels C Paliperidone manufacturer issues urgent recall. Medscape; [cited 2017 Jun 15]; Available from: https://www.medscape.com/viewarticle/881708
   Google Scholar
• Chue PS, MacKenzie EM, Chue JA, et al. The pharmacology and formulation of paliperidone extended release. Expert Rev Neurother. 2012;12:1399–1410.
   PubMed Web of Science ®Google Scholar
• Pani L, Marchese G. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. Expert Opin Drug Deliv. 2009;6:319–331.
   PubMed Web of Science ®Google Scholar
• Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am J Health Syst Pharm. 2008;65:403–413.
   PubMed Web of Science ®Google Scholar
• Malaterre V, Ogorka J, Loggia N, et al. Oral osmotically driven systems: 30 years of development and clinical use. Eur J Pharm Biopharm. 2009;73:311–323.
   PubMed Web of Science ®Google Scholar
• Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Control Release. 2002;79:7–27.
   PubMed Web of Science ®Google Scholar
• Dlugosz H, Nasrallah HA. Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opin Pharmacother. 2007;8:2307–2313.
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug-resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006;187:415–423.
   PubMed Web of Science ®Google Scholar
• Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163–169.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang JS, Markowitz JS, et al. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology. 2007;32:757–764.
   PubMed Web of Science ®Google Scholar
• Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302:1129–1134.
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
   PubMed Web of Science ®Google Scholar
• Takekita Y, Koshikawa Y, Fabbri C, et al. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry. 2016;16:172.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69:817–829.
   PubMed Web of Science ®Google Scholar
• Spina E, Cavallaro R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin Drug Saf. 2007;6:651–662.
   PubMed Web of Science ®Google Scholar
• Kandasamy A. Paliperidone as an alternative for risperidone in a case of schizophrenia with retrograde ejaculation. J Neuropsychiatry Clin Neurosci. 2012;24:E17–E18.
   PubMed Web of Science ®Google Scholar
• Lai CH. Improvements in micturition and urinary retention after switching from amisulpiride to paliperidone in a schizophrenic patient. J Neuropsychiatry Clin Neurosci. 2012;24:E11–E12.
   PubMed Web of Science ®Google Scholar
• Faure Walker N, Brinchmann K, Batura D. Linking the evidence between urinary retention and antipsychotic or antidepressant drugs: a systematic review. Neurourol Urodyn. 2016;35:866–874.
   PubMed Web of Science ®Google Scholar
• Sinha P, Gupta A, Reddi VS, et al. An exploratory study for bladder dysfunction in atypical antipsychotic-emergent urinary incontinence. Indian J Psychiatry. 2016;58:438–442.
   PubMed Web of Science ®Google Scholar
• Kumazaki H, Watanabe K, Imasaka Y, et al. Risperidone-associated urinary incontinence in patients with autistic disorder with mental retardation. J Clin Psychopharmacol. 2014;34:624–626.
   PubMed Web of Science ®Google Scholar
• Herguner S, Mukaddes NM. Risperidone-induced double incontinence. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1085–1086.
   PubMed Web of Science ®Google Scholar
• Farlow MR, Shamliyan TA. Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Eur Neuropsychopharmacol. 2017;27:217–231.
   PubMed Web of Science ®Google Scholar
• Mauri MC, Reggiori A, Paletta S, et al. Paliperidone for the treatment of schizophrenia and schizoaffective disorders – a drug safety evaluation. Expert Opin Drug Saf. 2017;16:365–379.
   PubMed Web of Science ®Google Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62.
   PubMed Web of Science ®Google Scholar
• Doan J, Zakrzewski-Jakubiak H, Roy J, et al. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013;47:324–332.
   PubMed Web of Science ®Google Scholar
• Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28.
   PubMed Web of Science ®Google Scholar
• Ponizovsky AM, Marom E, Ben-Laish M, et al. Trends in the use of antipsychotics in the Israeli inpatient population, 2004–2013. Isr J Health Policy Res. 2016;5(16):1–9.
   PubMedGoogle Scholar
• Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2016;12:407–422.
   PubMed Web of Science ®Google Scholar
• de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I. Psychosomatics. 2008;49:258–270.
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol. 2010;24:1011–1018.
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. Paliperidone: a review of clinical trial data and clinical implications. Clin Drug Investig. 2012;32:497–512.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Gen K, Otomo M, et al. Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia. Hum Psychopharmacol. 2014;29:244–250.
   PubMed Web of Science ®Google Scholar
• Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl). 2008;197:229–235.
   PubMed Web of Science ®Google Scholar
• Nazirizadeh Y, Vogel F, Bader W, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol. 2010;66:797–803.
   PubMed Web of Science ®Google Scholar
• Yang DS, Seong SJ, Yoon YR, et al. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia. J Psychopharmacol. 2014;28:341–348.
   PubMed Web of Science ®Google Scholar
• Chung YC, Cui Y, Kim MG, et al. Early predictors of a clinical response at 8 weeks in patients with first-episode psychosis treated with paliperidone ER. J Psychopharmacol. 2016;30:810–818.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Hashimoto K, Kubo K, et al. Interaction between paliperidone extended release and TS-1(R), an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient. Neuropsychiatr Dis Treat. 2013;9:317–320.
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Yeh HW, de Leon J. Role of statistical random-effects linear models in personalized medicine. Curr Pharmacogenomics Person Med. 2012;10:22–32.
   PubMedGoogle Scholar
• de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res. 2009;59:81–89.
   PubMed Web of Science ®Google Scholar
• Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol. 1997;50:223–239.
   PubMed Web of Science ®Google Scholar
• de Leon J. Evidence-based medicine versus personalized medicine: are they enemies?. J Clin Psychopharmacol. 2012;12(32):153–164.
   Google Scholar
• Paulzen M, Haen E, Grunder G, et al. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients-thinking of clinically relevant CYP2D6 interactions. J Psychopharmacol. 2016;30:803–809.
   PubMed Web of Science ®Google Scholar
• Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17:302–307.
   PubMed Web of Science ®Google Scholar
• Grunder G, Hiemke C, Paulzen M, et al. Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry. 2011;44:236–248.
   PubMed Web of Science ®Google Scholar
• Laupacis A, StrausS. Systematic reviews: time to address clinical and policy relevance as well as methodological rigor. Ann Intern Med. 2007;21(147):273–274.
   Google Scholar
• Lee JS, Ahn JH, Lee JI, et al. Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia. Clin Neuropharmacol. 2011;34:186–190.
   PubMed Web of Science ®Google Scholar
• Kim SW, Yoon JS, Kim YS, et al. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:228–235.
   PubMed Web of Science ®Google Scholar
• Yoon KS, Park TW, Yang JC, et al. Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers. Hum Psychopharmacol. 2012;27:305–314.
   PubMed Web of Science ®Google Scholar
• Kim SW, Chung YC, Lee YH, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacolo. 2012;27:267–274.
   PubMed Web of Science ®Google Scholar
• Jung SH, Yoon JS, Ahn YM, et al. Influencing factors and predictors of early response in schizophrenia patients receiving the paliperidone extended-release tablets (paliperidone ER). Psychiatry Investig. 2013;10:407–416.
   PubMed Web of Science ®Google Scholar
• Lee HW, Na KS, Jung SH, et al. The influence of previous antipsychotic polypharmacy versus monotherapy on the effectiveness of antipsychotic after switching to paliperidone extended-release. Clin Psychopharmacol Neurosci. 2013;11:152–157.
   PubMed Web of Science ®Google Scholar
• Kim EY, Chang SM, Shim JC, et al. Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. Curr Med Res Opin. 2013;29:1231–1240.
   PubMed Web of Science ®Google Scholar
• Na KS, Kim CE, Kim YS, et al. Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement. Hum Psychopharmacol. 2013;28:107–116.
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee HW, Jung SH, et al. Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy. Clin Psychopharmacol Neurosci. 2014;12:128–136.
   PubMed Web of Science ®Google Scholar
• Kang NI, Koo BH, Kim SW, et al. Efficacy and tolerability of paliperidone extended-release in the treatment of first-episode psychosis: an eight-week, open-label, multicenter trial. Clin Psychopharmacol Neurosci. 2016;14:261–269.
   PubMed Web of Science ®Google Scholar
• Chung YC, Cui Y, Sumiyoshi T, et al. Associations of fatty acids with cognition, psychopathology, and brain-derived neurotrophic factor levels in patients with first-episode schizophrenia and related disorders treated with paliperidone extended release. J Psychopharmacol. 2017;31:1556–1563.
   PubMed Web of Science ®Google Scholar
• Lepist EI, Ray AS. Renal transporter-mediated drug-drug interactions: are they clinically relevant? J Clin Pharmacol. 2016;56(S7):S73–S81.
   PubMedGoogle Scholar
• de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding. Rev Psiquiatr Salud Ment. 2015;8:167–188.
   PubMed Web of Science ®Google Scholar
• Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43:763–780.
   PubMed Web of Science ®Google Scholar
• de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians. Rev Psiquiatr Salud Ment. 2015;8:97–115.
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22:481–485.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Haen E, Grunder G, et al. Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under combined treatment. J Clin Psychopharmacol. 2016;36:554–561.
   PubMed Web of Science ®Google Scholar
• Cerveny L, Svecora L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregane X receptor pathways. Drug Metab Dispos. 2007;35:1032–1041.
   PubMed Web of Science ®Google Scholar
• Paulzen M, Orfanos S, Gründer G. Remission of drug-induced hepatitis after switching from risperidone to paliperidone. Am J Psychiatry. 2010;167:351–352.
   PubMed Web of Science ®Google Scholar
• Turkoz I, Bossie CA, Lindenmayer JP, et al. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry. 2011;11:21.
   PubMed Web of Science ®Google Scholar
• Gardner DM, Murphy AL, O’Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686–693.
   PubMed Web of Science ®Google Scholar
• Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69:440–447.
   PubMed Web of Science ®Google Scholar
• de Leon J. Training psychiatrist to think like pharmacologist; 2015.[cited 2017 Mar 15] Available from: http://inhn.org/home/courses/jose-de-leon-trainingpsychiatrists-to-think-like-pharmacologists.html
   Google Scholar